Clinerion and iHealth Group partner with Bioserv SMO to accelerate clinical research in Brazil by introducing Clinerion’s PRS to the Hospital São Vicente de Paulo

In concert with its Brazilian partner, the iHealth Group, Clinerion has agreed with Bioserv SMO to add Bioserv’s trial sites to the PRS platform. The Hospital São Vicente de Paulo is the first implementation, bringing another 540 thousand patient lives to Clinerion’s coverage in Brazil.

Bioserv SMO manages trial sites in the Rio Grande do Sul region of Brazil. The first implementation of PRS will take place at the Hospital São Vicente de Paulo, in the city of Passo Fundo. São Vicente de Paulo has 600 beds, and its hospital information system holds 540K patient lives.

The hospital’s 26 Principal Investigators specialize in multiple therapeutic areas, running studies in Phase Ib, II, III and IV on drugs and medical devices. Currently, they have 60 ongoing studies.

“We look forward to turning Rio Grande do Sul into a beacon for clinical research in Brazil,” says Keyla Deucher, PharmD, MBA, MsC, Director of Bioserv SMO. “The state Senator of Rio Grande do Sul, Senadora Ana Amélia Lemos, has been instrumental in the recent discussions and launch of the new Clinical Research law in Brazil. This law is opening doors for the future of clinical research in Brazil, increasing efficiency and security, and providing modern medicine for patients.”

“For the iHealth Group it is a great privilege, together with Clinerion, to carry out this great partnership with Bioserv SMO,” says Bruno Oliveira, founder and CIO of iHealth Group. “Digitalization of the health segment is a path of no return, and health facilities that are not prepared will have significant difficulties going forward. Bioserv is leading the pack in this matter and will certainly be an example for others following their lead.”

“Clinerion’s technology is designed to bring benefits born of disruption,” says Clinerion CEO, Ulf Claesson. “We are thrilled to partner with visionary organizations who decisively take huge technological steps toward creating new efficiencies in drug development and accelerating the launch of new medicines.”

About Bioserv SMO
Bioserv SMO is based in Passo Fundo, Rio Grande do Sul, working in partnership with Institutions of the Rio Grande do Sul state and across Brazil. We work in the area of general clinical research, including: Phase Ib to Phase IV projects in all therapeutic areas, drug studies, medical devices, cosmetics, and observational projects as well. We also support clinical projects design including recruiting sponsorships (researcher-sponsor studies). The company has participated in more than 100 clinical studies, with qualified professionals with experience in monitoring and coordinating studies in the pharmaceutical industry and research centers. Bioserv SMO centralizes the conduct of clinical studies, maintaining the same standards for all the studies. It allows to carry out studies with excellent ethical and data quality, to facilitate the regulatory and start up processes and to reduce their deadlines. In addition, it has a team with specific activities for patient recruitment, with the objective of keeping the level of inclusion of the studies always within the expected results.Bioserv SMO website: www.bioservsmo.com.br

About iHealth Group
The iHealth Group has a multidisciplinary team focused on serving the health informatics industry. Our team has extensive experience in this topic, leading the process of computerization of more than 30 Brazilian hospitals. Digital health transformation will enable us to improve communication with our patients, optimize our queues, improve the safety of our processes, expand our planning capacity, reduce costs, eliminate waste and, especially, do evidence-based management. However, we must understand that it is not the technology, but strategic management that will guide us correctly to the computerization of our health processes. IT cannot be a strategic goal, but an instrument to achieve a goal. iHealth Group website: www.ihealthgroup.com.br

About Clinerion
Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion’s PRS accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion’s solutions comply with international patient privacy and data security regulations.

Clinerion website: www.clinerion.com

Clinerion’s PRS: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem

For more information, please contact:
Le Vin Chin
Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54
media@clinerion.com